HBHannah Ursula Clara Brass

Hannah Ursula Clara Brass

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannah Ursula Clara Brass has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimized prodigiosin production with Pseudomonas putida KT2440 using parallelized noninvasive online monitoring

    by Carl Brehl, Hannah U. C. Brass, Clara Lüchtrath, Lukas Böckmann, Nina Ihling, Thomas Classen, Jörg Pietruszka, Jochen Büchs

    The red pigment prodigiosin is of high pharmaceutical interest, due to its potential applications as an antitumor drug and antibiotic agent. As previously demonstrated, Pseudomonas putida KT2440 is a suitable host for prodigiosin production , as it exhibits high tolerance toward the antimicrobial properties of prodigiosin. So far, prodigiosin concentrations of up to 94 mg/L have been achieved in shake flask cultivations. For the characterization and optimization of the prodigiosin production process, the scattered light of P. putida and fluorescence of prodigiosin was measured. The excitation and emission wavelengths for prodigiosin measurement were analyzed by recording 2D fluorescence spectra. The strongest prodigiosin fluorescence was obtained at a wavelength combination of 535/560 nm. By reducing the temperature to 18 °C and using 16 g/L glucose, the prodigiosin concentration was more than doubled compared with the initial cultivation conditions. The obtained results demonstrate the capabilities of parallelized microscale cultivations combined with noninvasive online monitoring of fluorescence for rapid bioprocess development, using prodigiosin as a molecule of current biotechnological interest.


  • Open Access

    Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

    by Lena Berning, David Schlütermann, Annabelle Friedrich, Niklas Berleth, Yadong Sun, Wenxian Wu, María José Mendiburo, Jana Deitersen, Hannah U. C. Brass, Margaretha A. Skowron, et al.

    Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various bacteria, exerts different biological activities including the modulation of these two cellular stress response pathways. We analyzed the effect of prodigiosin on protein levels of different autophagy- and apoptosis-related proteins in cisplatin-sensitive and -resistant urothelial carcinoma cells (UCCs). Furthermore, we investigated the effect on cell viability of prodigiosin alone or in combination with cisplatin. We made use of four different pairs of cisplatin-sensitive and -resistant UCCs. We found that prodigiosin blocked autophagy in UCCs and re-sensitized cisplatin-resistant cells to apoptotic cell death. Furthermore, we found that prodigiosin is a potent anticancer agent with nanomolar IC50 values in all tested UCCs. In combination studies, we observed that prodigiosin sensitized both cisplatin-sensitive and -resistant urothelial carcinoma cell lines to cisplatin treatment with synergistic effects in most tested cell lines. These effects of prodigiosin are at least partially mediated by altering lysosomal function, since we detected reduced activities of cathepsin B and L. We propose that prodigiosin is a promising candidate for the therapy of cisplatin-resistant urothelial carcinomas, either as a single agent or in combinatory therapeutic approaches.


  • KnowVolution of prodigiosin ligase PigC towards condensation of short-chain prodiginines

    by Stefanie Brands, Hannah U. C. Brass, Andreas S. Klein, Jarno G. Sikkens, Mehdi D. Davari, Jörg Pietruszka, Anna Joëlle Ruff, Ulrich Schwaneberg

    Prodigiosin ligase PigC catalyses the final condensation step in the prodigiosin biosynthesis of Serratia marcescens, in which two pyrrolic precursor molecules are fused linearly to form tripyrrolic red prodiginines. Prodiginine compounds attracted interest as pharmaceutical agents lately since their structural elucidation in the 1960s due to their multiple bioactivities (e.g., antibiotic, nematicidal or anticancer effects). As a key enzyme in the prodigiosin biosynthesis pathway, PigC presents a bottleneck for efficient broad-range prodiginine production because of its limited substrate acceptance. In particular, biosynthesis of short-chain prodiginines is of high synthetic interest due to their effective anticancer properties. In this study, PigC was successfully engineered to efficiently accept short-chain pyrroles following the KnowVolution strategy, which provided variants with up to 10.7-fold increased kcat (7.5 ± 0.4 min−1 compared to 0.7 ± 0.1 min−1 for the PigC wild type), and a nearly 40-fold enhanced catalytic efficiency (kcat/KM = 23.9 ± 3.6 mM−1 s−1 compared to 0.6 ± 0.1 mM−1 s−1 for the PigC wild type) towards short-chain pyrroles. The final and most active PigC variant S1 carried two amino acid substitutions (I365G/M671V) in the substrate-binding domain close to a substrate tunnel, and showed a pronounced preference for small pyrroles. In summary, the directed evolution campaign on PigC provided engineered variants to open a biosynthetic route for short-chain prodiginines.


  • Understanding substrate binding and the role of gatekeeping residues in PigC access tunnels

    by Stefanie Brands, Jarno G. Sikkens, Mehdi D. Davari, Hannah U. C. Brass, Andreas S. Klein, Jörg Pietruszka, Anna Joëlle Ruff, Ulrich Schwaneberg

    Prodigiosin ligase PigC has been engineered by semi-rational design to accept short chain-pyrroles, providing molecular understanding of access tunnels and the substrate-binding pocket.


  • Open Access

    Novel Prodiginine Derivatives Demonstrate Bioactivities on Plants, Nematodes, and Fungi

    by Samer S. Habash, Hannah U. C. Brass, Andreas S. Klein, David P. Klebl, Tim Moritz Weber, Thomas Classen, Jörg Pietruszka, Florian M. W. Grundler, A. Sylvia S. Schleker

    Bacterial metabolites represent an invaluable source of bioactive molecules which can be used as such or serve as chemical frameworks for developing new antimicrobial compounds for various applications including crop protection against pathogens. Prodiginines are tripyrrolic, red-colored compounds produced by many bacterial species. Recently, due to the use of chemical-, bio-, or mutasynthesis, a novel group of prodiginines was generated. In our study, we perform different assays to evaluate the effects of prodigiosin and five derivatives on nematodes and plant pathogenic fungi as well as on plant development. Our results showed that prodigiosin and the derivatives were active against the bacterial feeding nematode Caenorhabditis elegans in a concentration- and derivative-dependent manner while a direct effect on infective juveniles of the plant parasitic nematode Heterodera schachtii was observed for prodigiosin only. All compounds were found to be active against the plant pathogenic fungi Phoma lingam and Sclerotinia sclerotiorum. Efficacy varied depending on compound concentration and chemical structure. We observed that prodigiosin (1), the 12 ring- 9, and hexenol 10 derivatives are neutral or even positive for growth of Arabidopsis thaliana depending on the applied compound concentration, whereas other derivatives appear to be suppressive. Our infection assays revealed that the total number of developed H. schachtii individuals on A. thaliana was decreased to 50% in the presence of compounds 1 or 9. Furthermore, female nematodes and their associated syncytia were smaller in size. Prodiginines seem to indirectly inhibit H. schachtii parasitism of the plant. Further research is needed to elucidate their mode of action. Our results indicate that prodiginines are promising metabolites that have the potential to be developed into novel antinematodal and antifungal agents.


  • A colourimetric high-throughput screening system for directed evolution of prodigiosin ligase PigC

    by Stefanie Brands, Hannah U. C. Brass, Andreas S. Klein, Jörg Pietruszka, Anna Joëlle Ruff, Ulrich Schwaneberg

    A colourimetric high-throughput screening system was established for directed evolution of prodigiosin ligase PigC. The two-step system consists of a colony prescreening test and a subsequent photometric 96-well plate assay. Screening PigC epPCR libraries in Pseudomonas putida revealed a PigC variant that achieved a 2.9× increased yield of prodiginine derivatives.


  • Cover Feature: Preparation of Cyclic Prodiginines by Mutasynthesis in Pseudomonas putida KT2440 (ChemBioChem 14/2018)

    by Andreas Sebastian Klein, Hannah Ursula Clara Brass, David Paul Klebl, Thomas Classen, Anita Loeschcke, Thomas Drepper, Sonja Sievers, Karl‐Erich Jaeger, Jörg Pietruszka

  • Preparation of Cyclic Prodiginines by Mutasynthesis in Pseudomonas putida KT2440

    by Andreas Sebastian Klein, Hannah Ursula Clara Brass, David Paul Klebl, Thomnas Classen, Anita Loeschcke, Thomas Drepper, Sonja Sievers, Karl‐Erich Jaeger, Joerg Pietruszka

    Prodiginines are a group of naturally occurring pyrrole alkaloids produced by various microorganisms and known for their broad biological activities. The production of nature‐inspired cyclic prodiginines was enabled by combining organic synthesis with a mutasynthesis approach based on the GRAS (generally recognized as safe) certified host strain Pseudomonas putida KT2440. The newly prepared prodiginines exerted antimicrobial effects against relevant alternative biotechnological microbial hosts whereas P. putida itself exhibited remarkable tolerance against all tested prodiginines, thus corroborating the bacterium's exceptional suitability as a mutasynthesis host for the production of these cytotoxic secondary metabolites. Moreover, the produced cyclic prodiginines proved to be autophagy modulators in human breast cancer cells. One promising cyclic prodiginine derivative stood out, being twice as potent as prodigiosin, the most prominent member of the prodiginine family, and its synthetic derivative obatoclax mesylate.


  • New Prodigiosin Derivatives Obtained by Mutasynthesis in Pseudomonas putida

    by Andreas S. Klein, Andreas Domröse, Patrick Bongen, Hannah U. C. Brass, Thomas Classen, Anita Loeschcke, Thomas Drepper, Luca Laraia, Sonja Sievers, Karl-Erich Jaeger, et al.

    The deeply red-colored natural compound prodigiosin is a representative of the prodiginine alkaloid family, which possesses bioactivities as antimicrobial, antitumor, and antimalarial agents. Various bacteria including the opportunistic human pathogen Serratia marcescens and different members of the Streptomycetaceae and Pseudoalteromonadaceae produce prodiginines. In addition, these microbes generally accumulate many structurally related alkaloids making efficient prodiginine synthesis and purification difficult and expensive. Furthermore, it is known that structurally different natural prodiginine variants display differential bioactivities. In the herein described mutasynthesis approach, 13 different derivatives of prodigiosin were obtained utilizing the GRAS (generally recognized as safe) classified strain Pseudomonas putida KT2440. Genetic engineering of the prodigiosin pathway together with incorporation of synthetic intermediates thus resulted in the formation of a so far unprecedented structural diversity of new prodiginine derivatives in P. putida. Furthermore, the formed products allow reliable conclusions regarding the substrate specificity of PigC, the final condensing enzyme in the prodigiosin biosynthesis pathway of S. marcescens. The biological activity of prodigiosin toward modulation of autophagy was preserved in prodiginine derivatives. One prodiginine derivative displayed more potent autophagy inhibitory activity than the parent compound or the synthetic clinical candidate obatoclax.